SCHEMBL1367145

SCHEMBL1367145

COc1ccc(C=CC(=O)CC(=O)c2cc3c(OC)cccc3oc2=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.61
MAPT P10636 3/20 0.53
KMT2A Q03164 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
PLIN1 O60240 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
RAB9A P51151 1/20 0.53
PLIN5 Q00G26 1/20 0.53
ABHD5 Q8WTS1 1/20 0.53
GSK3B P49841 1/20 0.52
MAOA P21397 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
BACE1 P56817 2/20 0.46
CNR1 P21554 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
NFE2L2 Q16236 1/20 0.44
CNR2 P34972 1/20 0.43
APP P05067 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368562 1.00 MAOB (0.61) MAOBMAPTKMT2AKDM4EMEN1
SCHEMBL1367143 1.00 MAOB (0.61) MAOBMAPTKMT2AKDM4EMEN1
SCHEMBL1366656 0.89 MAOB (0.63) MAOBMAPTKMT2AKDM4EMEN1
SCHEMBL1367316 0.89 MAOB (0.63) MAOBMAPTKMT2AKDM4EMEN1
SCHEMBL1366661 0.89 MAOB (0.63) MAOBMAPTKMT2AKDM4EMEN1
SCHEMBL1369259 0.86 MAOB (0.61) MAOBMAPTKMT2AKDM4EMEN1
SCHEMBL1368512 0.86 MAOB (0.61) MAOBMAPTKMT2AKDM4EMEN1
SCHEMBL1368510 0.86 MAOB (0.61) MAOBMAPTKMT2AKDM4EMEN1
SCHEMBL1368398 0.83 MAOB (0.51) MAOBMAPTKMT2AKDM4EMEN1
SCHEMBL1368401 0.83 MAOB (0.51) MAOBMAPTKMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS MAOB 2929/4885MAPT 4718/4885KMT2A 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.